ERBB2 and breast carcinoma: Giredestrant did outperform anastrozole in reducing Ki67 expression and inducing complete cell cycle arrest when used as neoadjuvant therapy for previously untreated patients from the coopERA study in postmenopausal women with hormone receptor–positive, HER2 − early breast cancer [80].